Contemporary Management of CLL

Contemporary Management of CLL

Episodes

Specialty:

All

Year:

All

EP. 1: Selecting Frontline Therapy to Treat CLL

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

EP. 2: BTK Monotherapy for Frontline CLL

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

EP. 3: Anti-CD20/BTKi Therapy for Frontline CLL

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

EP. 4: Anti-BCL2/CD20 Combination Therapy for Frontline CLL

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

EP. 5: Frontline CLL Treatment With Fixed-Duration Regimens

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

EP. 6: Minimal Residual Disease in CLL

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

EP. 7: Frontline CLL: Treatment Algorithms

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

EP. 8: CLL Treatment Approaches During COVID-19

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

EP. 9: CLL Patient Management During COVID-19 and Telehealth

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

EP. 10: Therapeutic Sequencing in Relapsed/Refractory CLL

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

EP. 11: Relapsed/Refractory CLL: Repeat Molecular Testing

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

EP. 12: Allogeneic Transplantation for CLL

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

EP. 13: Frontline CLL Treatment: Addressing Unmet Needs

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

January 8th 2021

EP. 14: Relapsed/Refractory CLL Treatment: Addressing Unmet Needs

ByAlan P. Skarbnik, MD, Novant Health Cancer Institute,Catherine C. Coombs, MD, UNC School of Medicine,Danielle M. Brander, MD, Duke Cancer Institute

February 8th 2021

Trending on OncLive

FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer

FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer

Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial

Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer

Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape